Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals
NESS ZIONA, Israel – March 18, 2019 – Mapi Pharma Ltd., a fully integrated, clinical, late stagebiopharmaceutical company, announced today that it has received complementary funding fromthe Israeli Ministry of the Economy to build a new sterile production plant for GA Depot injectableproducts. The approved financing plan is for a pioneering production plant for the manufacturingof a slow release formulation of Glatiramer Acetate (GA) (Copaxone®) for treating multiplesclerosis. The plant will be built in Jerusalem, a Zone A region, allowing tax and grants benefits, inan investment of over 46 million NIS, of which the grant is set at over 9 million NIS. The plant willlead to the hiring of an additional 30 employees and all sales are expected to be exported.
